Opinion of the Transparency Council – amiloridum + hydrochlorothiazidum
At its meeting on 9 June 2025,, the Transparency Council adopted opinion No. 103/2025 on the inclusion of medicinal products containing the active substances amiloridum + hydrochlorothiazidum in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. nephrogenic diabetes insipidus